|
DBVT | Dbv Technologies S.a. |
|
|
DBVT | Dbv Technologies S.a. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 0.35 |
| Leverage | 25.66% |
| Market Cap | $ 1.5B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -167.0m |
| Margin | -2891.09% |
DBV Technologies SA, a clinical-stage biopharmaceutical company, is dedicated to the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, France.